Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.2 USD | +0.59% | -1.60% | -13.66% |
May. 03 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
May. 02 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.66% | 3.4B | |
+5.50% | 111B | |
+11.01% | 105B | |
-12.26% | 22.34B | |
-3.00% | 21.93B | |
-6.13% | 18.59B | |
-36.52% | 18.12B | |
-9.51% | 16.96B | |
+2.91% | 13.7B | |
+37.46% | 12.45B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-06-2023 08